Endocrine-Related Cancer

Article	Citations
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	78
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	55
Radioiodine: 80 years and counting; the past, present, and future	49
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	44
Targeting growth hormone in cancer: future perspectives	42
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	42
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma	35
Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation	34
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer	33
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	31
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy	27
Acknowledgement to reviewers	27
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	26
Celebrating the 80th anniversary of hormone ablation for prostate cancer	25
Advancements and challenges in pheochromocytoma and paraganglioma research: a collection of insights	24
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	24
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	24
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review	23
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy	22
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma	22
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis	21
Genetic disorders and insulinoma/glucagonoma	20
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	20
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	20
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors	20

Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	19
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	19
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	18
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer	18
Acknowledgement to reviewers	18
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	18
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	17
Thyroid status regulates the tumor microenvironment delineating breast cancer fate	17
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors	17
Congenital hypothyroidism and thyroid cancer	17
AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes	17
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment	16
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma	16
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	16
Update on the genetics of paragangliomas	16
Nutrition, GH/IGF-1 signaling, and cancer	16
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	16
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	16
The role of vitamin D in breast cancer risk and progression	15
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	15
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	15
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine	15
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	14
Aggressive versus indolent insulinomas: new clinicopathological insights	13
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 2021	13
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	13
Deiodinases in thyroid tumorigenesis	12
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	12
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	12
Radioiodine treatment: an historical and future perspective	12
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	12
Genomic alterations impact cell cycle-related genes during prostate cancer progression	11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms	11
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms	11
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	11
Molecular alterations in Hürthle cell nodules and preoperative cancer risk	11
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome	11
Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS	11
DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition	11
Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine	11
Talking about sex: erectile dysfunction in the oncology patient	10
Non-pituitary GH regulation of the tissue microenvironment	10
Clinical and basic research implications of the article ‘IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer’	10
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	10
Beyond the three P’s: adrenal involvement in MEN1	10
Primary tumour resection in metastasised adrenocortical carcinoma	10
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome	10
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer	10
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	10
Activation of the HIF1α/TIMP1/MT6-MMP pathway is associated with invasion in pituitary null cell adenomas	10

The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy	10
Germline CDKN1B variant type and site are associated with phenotype in MEN4	9
PARP inhibitors in advanced prostate cancer: when to use them?	9
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis	9
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo	9
Genome-wide crosstalk between steroid receptors in breast and prostate cancers	9
Cancer clocks in tumourigenesis: the p53 pathway and beyond	9
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	9
Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer	8
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	8
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	8
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	8
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	8
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes	8
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	8
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	8
Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal	8
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures	8
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	8
Prostate cancer and bone: clinical presentation and molecular mechanisms	8
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	8
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress	8
Sexual dimorphism in medullary thyroid cancer aggressiveness	7
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	7
Prognostic stratification for patients with neuroendocrine tumours receiving 177Lu-Dotatate	7
A study of acromegaly-associated headache with somatostatin analgesia	7
Transcriptomic landscape of radiation-induced murine thyroid proliferative lesions	7
Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes	7
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	7
Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview	7
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs	7
Mendelian randomization to investigate the link between TSH and thyroid cancer	7
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	7
Persistent pre-exhausted CD8+ T cells shape the tumor immune microenvironment in anaplastic thyroid cancer	7
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	6
Key factors for effective mitotane therapy in children with adrenocortical carcinoma	6
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	6
Gender-affirming care and endocrine-related cancers	6
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	6
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	6
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	6
The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma	6
Cellular mechanisms of RET receptor dysfunction in multiple endocrine neoplasia 2	6
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality	6
Whole-exome sequencing of rectal neuroendocrine tumors	6
Mechanisms of RET-mediated signal transduction	6
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	6
In memoriam: Charis Eng MD PhD (1962–2024)	6
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	6
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway	6
Interventional vs surgical procedures in localized/nonmetastatic insulinomas (ablation vs surgery)	6
Cushing syndrome from an ACTH-producing pheochromocytoma or paraganglioma: structured review of 94 cases	5
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	5
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	5
Insulin resistance and racial disparities in breast cancer prognosis: a multi-center cohort study	5
Novel insights in cell cycle dysregulation during prostate cancer progression	5
Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours	5
Response to Letter to the Editor regarding ‘Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma’	5
Long-term safety of growth hormone replacement therapy in survivors of cancer and tumors of the pituitary region	5
The effects of exercise and diet on sex steroids in breast cancer survivors	5
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors	5
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians	5
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	5
Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy	5
Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET	5
Therapy considerations in neuroendocrine prostate cancer: what next?	5
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	5
Glucagon and insulin: 100 years young	5
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers	4
Alert to US physicians: DHEA, widely used as an OTC androgen supplement, may exacerbate COVID-19	4
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	4
The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings	4
Pituitary-testis axis dysfunction following adjuvant androgen deprivation therapy	4
Needle tract seeding of thyroid cancer after biopsy of distant metastasis: a retrospective cohort	4
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	4
The tumor microenvironment and immune responses in prostate cancer patients	4
Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases	4

Antitumor immune response is associated with favorable survival in GEP-NEN G3	4
Immunotherapy-induced isolated ACTH deficiency in cancer therapy	4
MicroRNAs as regulators of tumor metabolism	4
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism	4
TREM1 fosters an immunosuppressive tumor microenvironment in papillary thyroid cancer	4
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	4
Pacak–Zhuang syndrome: a model providing new insights into tumor syndromes	4
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns	4
Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline	4
Role of circadian rhythm disorders on EMT and tumour–immune interactions in endocrine-related cancers	4
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	4
Androgen receptor mutations for precision medicine in prostate cancer	4
Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer	4
Factors associated with grade progression in pancreatic neuroendocrine tumors	4
Inhibition of activin signalling reduces the growth of LβT2 gonadotroph pituitary tumours in mouse	3
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	3
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	3
Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?	3
GH-dependent growth of experimentally induced carcinomas in vivo	3
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	3
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?	3
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	3
Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors	3
IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer	3
Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis	3
Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors	3
Type 2 deiodinase is expressed in anaplastic thyroid carcinoma and its inhibition causes cell senescence	3
lncRNA H19 binds VGF and promotes pNEN progression via PI3K/AKT/CREB signaling	3
The role of membrane mucin MUC4 in breast cancer metastasis	3
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	3
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues	3
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	2
Dysregulation of splicing variants and spliceosome components in breast cancer	2
Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism	2
Somatostatin receptor radionuclide therapy in neuroendocrine tumors	2
Hypothyroidism induces oxidative stress and DNA damage in breast	2
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	2
Immunotherapy for endocrine tumours: a clinician’s perspective	2
Second primary cancers and survival among neuroendocrine tumor patients	2
Leptin-elicited PBX3 confers letrozole resistance in breast cancer	2
The thyroid risk score (TRS) for nodules with indeterminate cytology	2
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	2
The complex landscape of luminal breast cancer	2
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	2
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	2
Therapeutic inhibition of ATR in differentiated thyroid cancer	2
SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?	2
Prognostic transcriptome classes of duodenopancreatic neuroendocrine tumors	2
Bioengineered in vitro three-dimensional tumor models in endocrine cancers	2
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	2
RAB5A in triple-negative breast cancer: a critical role in macrophage reshaping in an exosomal miR-21-dependent manner	2
Percutaneous ablation of low-risk papillary thyroid cancer	2
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	2
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	2
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	2
100 years of the Warburg effect: a historical perspective	2
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	2
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	2
Effect of TSH levels during active surveillance of PTMC according to age	2
Na+/I− symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy	2
HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs	2
C/EBPβ mediates anti-proliferative effects of 1,25(OH)2D on differentiated thyroid carcinoma cells	2
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	2
Precocious puberty due to intracranial germ cell tumors: a case–control study	2
Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites	2
Disease relapse in relation to lymph node sampling in lung carcinoid patients	2
Living with a RET gene mutation: patient perspectives	2
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	2